News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
Accelerating ALS Drug Development: InnoSer’s Available In Vivo Models for Preclinical Research
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder lacking highly effective disease-modifying treatment or a cure. The often-heterogenous course of ALS underlines the need for modelling the different disease aspects in multiple, distinct models...
In Vitro & In Vivo Parkinson’s Disease Models: Understanding Their Role in Preclinical Drug Development
Parkinson’s disease (PD) is a complex neurodegenerative disorder that affects millions of people worldwide. Different experimental models recapitulate distinct pathophysiological features of PD. Selecting the most appropriate model for a specific research question is...
Choosing The Right ADPKD Mouse Model for Advancing your Rare Disease Research
To support the development of new therapies for autosomal dominant polycystic kidney disease, we offer a kidney-specific PKD1 knockout ADPKD mouse model. The age-dependent nature of cyst formation allows for tailoring of the model, enabling researchers to choose the...
InnoSer expands its preclinical neuroscience expertise with the acquisition of Sylics
This strategic acquisition substantially expands InnoSer’s preclinical neurology portfolio, adding in vivo rodent models for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, as well as key rare genetic disease...
InnoSer expands preclinical cancer readout capabilities through acquisition of new imagers.
Getting closer to understanding cancer through the adoption of technological advancements is crucial in providing deeper insights for our customers. By building robust and reliable dossiers for promising drug candidates moving into clinical trials, we can help our...
Discussing innovation and the PDX/O platform at SINERGIA Summer School
We strive to stay at the forefront of biotechnological developments and to constantly incorporate innovation in our offerings - this is essential to be able to develop more reliable drug development platforms and avoid high drug attrition rates. Study director...
info@innoserlaboratories.com